Quotient Sciences Appoints Thierry Van Nieuwenhove as CEO

Read Now

Quotient Sciences wins Medilink UK Healthcare Business Award for Outstanding Achievement

Quotient Sciences (“Quotient”), the drug development services organization, has won the Outstanding Achievement Award at the 2019 Medilink UK Healthcare Business Awards, held last night.

The Awards recognize organizations who have made significant contributions to life sciences and who have excelled in their individual categories across the healthcare industry. The Medilink UK winners were chosen from an exclusive shortlist comprised entirely of winners from each of the regional Medilink awards.

The Outstanding Achievement award recognizes Quotient’s momentous success and continued development. Quotient has experienced significant growth and global expansion following a series of acquisitions and facility investments in the U.K. and U.S. and now employs over 850 employees across six operating sites.  Quotient was also recognized for its innovative approach to drug development, termed Translational Pharmaceutics®, which enables significant shortening of drug development times and reduced costs for biotechnology and pharmaceutical clients throughout the world.

Mark Egerton, CEO Quotient Sciences said, “We are delighted to have won the Outstanding Achievement award. It is great recognition for all the hard work and continuous commitment and dedication of our staff. Well done to the team for delivering this success”

View press release (PDF)